Received Apr 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
General Rash; Itchiness; possible hives; Redness to Cheeks that were Warm to touch; This spontaneous report was received from a Physician and refers to a 13-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions included Environmental allergies. Concomitant therapies were not reported. On 28-FEB-2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) solution for injection (lot #, dose, route of administration, anatomical location of vaccine and expiration date were not reported) for Prophylaxis. On 28-FEBB-2025, experienced general rash, itchiness and redness to cheeks that were "warm to touch" after receiving first dose, additionally, he experienced rash and redness approximately one hour after receiving injection. Patient was given a dose of Fexofenadine (ALLEGRA) on the same day. The reporter said that the symptoms continued a second day and was given a second dose of Fexofenadine (ALLEGRA). The reporter stated that on the third day patient came into clinic for consultation and remnants of a rash and "possible hives" were seen. No other findings were notice. At the reporting time, the outcome of the events was unknown. The causal relationship between the events and Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) was unknown.
Environmental allergy